Abstract
In patients (pts) with advanced NSCLC who progress after platinum-doublet chemotherapy (PDC) and immune checkpoint inhibitor therapy, treatment options are limited; DTX is most commonly used in this setting. Preclinical data with CAN, a selective interleukin-1β inhibitor, plus DTX showed greater tumor growth reduction than DTX alone and decreased immunosuppressive cell infiltration in the tumor microenvironment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
